TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26761518
Drug: Any vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any vaccine arm
Study: 22508813
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg two times per day)
Study: 15970809
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate therapy until the onset of diuresis (urine output >100 mL/hr for 2 consecutive hours)
Study: 15970809
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate therapy for 24 hours (control group)
Study: 11552905
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg)
Study: 11552905
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg) plus bedtime H2-blocker
Study: 11552905
Drug: Bedtime H2RA
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime H2RA added to proton pump inhibitor b.d.
Study: 9314118
Drug: Lamivudine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (5 to 600 mg per day) for 4 weeks
Study: 8365298
Drug: albuterol by
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol by metered dose inhaler (0.4 mg)
Study: 8365298
Drug: albuterol by
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol by wet nebulizer (2.5 mg)
Study: 3076999
Drug: RE7 (rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RE7 (rifampicin and ethambutol daily)
Study: 3076999
Drug: RE3 (rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RE3 (rifampicin and ethambutol thrice weekly)
Study: 21659893
Drug: β-alanine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-alanine (4 g·d in powdered capsule form)
Study: 18076750
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking cessation treatment
Study: 18076750
Drug: Delayed smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed smoking cessation treatment
Study: 15228924
Drug: Intravenous heroin
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heroin treatment
Study: 3456079
Drug: Methotrexate (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (1000 mg per square meter) infused over 24 hours
Study: 16968848
Drug: Losartan-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan-based treatment regimen
Study: 16968848
Drug: Atenolol-based treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol-based treatment regimen
Study: 12543279
Drug: Dawn-dusk simulation
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dawn-dusk simulation (DDS) light therapy
Study: 11239099
Drug: Outpatient commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient commitment with case management services and outpatient treatment
Study: 11239099
Drug: Sustained outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained outpatient commitment combined with intensive outpatient treatment
Study: 2906346
Drug: Triphasic combination
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic combination of gestodene and ethinyl estradiol
Study: 2906346
Drug: Low-dose triphasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triphasic combination of levonorgestrel and ethinyl estradiol
Study: 31771942
Drug: Aquamin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquamin (800 mg of calcium per day)
Study: 23159276
Drug: fesoterodine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine (4 mg daily for 4 weeks with an optional increase to 8 mg)
Study: 21385509
Drug: Resveratrol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (2 x 5 mg orally)
Study: 18171453
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg methylphenidate, parent training programme
Study: 18171453
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg methylphenidate, parent support programme
Study: 18171453
Drug: placebo medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication, parent training
Study: 18171453
Drug: placebo medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo medication, parent support
Study: 14629104
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with sodium porfimer administered 48 hours before photoradiation.
Study: 6134535
Drug: Vecuronium 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.03 mg kg‐1
Study: 6134535
Drug: Pancuronium 0.042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.042 mg kg‐1
Study: 31820032
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) in ICUs with low prevalence of antibiotic resistance
Study: 31820032
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) in ICUs with moderate-to-high prevalence of antibiotic resistance
Study: 30545718
Drug: Classic carotid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic carotid endarterectomy with xenopericardial patch closure
Study: 25738786
Drug: Standard method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard method of warming (heat-retaining caps, warmed intravenous and irrigation fluids, and warmed blankets)
Study: 23939292
Drug: Lotrafilcon B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafilcon B silicone hydrogel lenses (daily wear, monthly replacement)
Study: 17237662
Drug: IA CRH
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA CRH (10 microg) + naloxone (0.12 mg)
Study: 15566918
Drug: Azithromycin therapy
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin therapy
Study: 8659195
Drug: Running or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running or swimming therapy (according to the stamina principle)
Study: 8659195
Drug: Nifedipine therapy
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine therapy (40‐60 mg/d)
Study: 2258250
Drug: Droxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam (20 mg/day)
Study: 29685813
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TOBI 300 mg)
Study: 27987240
Drug: Dapagliflozin 5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5/10 mg
Study: 24691799
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg and Fenofibrate 145 mg (simultaneous dosing)
Study: 24691799
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg and Fenofibrate 145 mg (staggered dosing)
Study: 22978099
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy using lymphocytes of spouses (Control)
Study: 15604959
Drug: Early lymphoscintigraphy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early lymphoscintigraphy (15 minutes to 4 hours after radionuclide injection)
Study: 15604959
Drug: Delayed lymphoscintigraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed lymphoscintigraphy (18‐24 hours after radionuclide injection)
Study: 18452257
Drug: Lowering the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering the fasting plasma glucose (FPG) criteria for IFG from 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL)
Study: 18452257
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with IFG (5.6‐7.0 mmol/L)
Study: 15845691
Drug: DM-TEA (Dextromethorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM-TEA (Dextromethorphan 40 mg IM combined with TEA)
Study: 15845691
Drug: CPM-TEA (Chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM-TEA (Chlorpheniramine maleate 20 mg combined with TEA)
Study: 15845691
Drug: CPM-GA (Chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPM-GA (Chlorpheniramine maleate 20 mg with general anesthesia)
Study: 12425755
Drug: G‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 5 microg/kg subcutaneously daily
Study: 12425755
Drug: leridistim 5
Normalized name: Leridistim
DrugBank: Leridistim (DB15095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: leridistim 5 microg/kg subcutaneously daily
Study: 10509850
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 (0.8% polymer concentration)
Study: 6140700
Drug: DL‐308 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐308 (10 mg)
Study: 6140700
Drug: DL‐308 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐308 (20 mg)
Study: 1106447
Drug: oxazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxazepam (30 mg)
Study: 29800026
Drug: Sirolimus gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus gel, 0.2%
Study: 26999197
Drug: Control (Sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Sugar solution)
Study: 23878109
Drug: Scutellaria lateriflora
Normalized name: Scutellaria lateriflora
DrugBank: Scutellaria lateriflora (DB14339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scutellaria lateriflora (350 mg) three times daily for two weeks
Study: 23878109
Drug: Scutellaria lateriflora
Normalized name: Scutellaria lateriflora
DrugBank: Scutellaria lateriflora (DB14339)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scutellaria lateriflora (350 mg)
Study: 9704834
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.05% cream once daily
Study: 9704834
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate 0.05% cream twice daily
Study: 9704834
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FP and CB)
Study: 9345395
Drug: 3 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Study: 9345395
Drug: 9 MIU
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Study: 2565767
Drug: Alpidem (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (150 mg/day)
Study: 348406
Drug: Hydrocortisone valerate
Normalized name: Hydrocortisone Valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone valerate cream (0.2 percent)
Study: 348406
Drug: Fluorinated beta-methasone
Normalized name: beta-Methasone alcohol
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorinated beta-methasone valerate cream (0.1 percent)
Study: 348406
Drug: Hydrocortisone cream
Normalized name: Hydrocortisone Cream
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone cream (0.1 percent)
Study: 9348547
Drug: Medication-free phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication-free phase
Study: 8406169
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ursodeoxycholic acid
Study: 3465375
Drug: Intravenous Prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Prostaglandin F2-alpha
Study: 3465375
Drug: Intramuscular Prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Prostaglandin F2-alpha
Study: 30249630
Drug: Initial triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial triple combination therapy with metformin, dapagliflozin, and saxagliptin
Study: 30249630
Drug: Conventional stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stepwise add-on therapy
Study: 26767508
Drug: 4 Pillars
Normalized name: BACCHARIS PILULARIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Pillars Immunization Toolkit, early delivery of donated vaccine, staff education, feedback on progress
Study: 20697276
Drug: Gatifloxacin (0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (0.3% gatifloxacin ophthalmic solution)
Study: 20697276
Drug: Moxifloxacin (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (0.5% moxifloxacin hydrochloride ophthalmic solution)
Study: 18443573
Drug: D2 (4
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D2 (4 mg/1.25 mg)
Study: 18443573
Drug: D1 (2
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1 (2 mg/0.625 mg)
Study: 1852179
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy (surgical treatment)
Study: 31955956
Drug: Hypokalemia (<3.0mEq/L)
Normalized name: Drugs for treatment of hyperkalemia and hyperphosphatemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypokalemia (<3.0mEq/L)
Study: 31955956
Drug: Hyperkalemia (>6.0mEq/L)
Normalized name: 6-ammonio-L-norleucine
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyperkalemia (>6.0mEq/L)
Study: 31955956
Drug: Normokalemia (3.5-5mEq/L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normokalemia (3.5-5mEq/L)
Study: 28906561
Drug: Intravenous rolapitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rolapitant (166.5 mg)
Study: 28906561
Drug: Oral rolapitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rolapitant (180 mg)
Study: 19120077
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus (target trough levels >10 ng/mL) and corticosteroids; n = 183
Study: 19120077
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2g/day, reduced-dose tacrolimus (target trough levels </=8 ng/mL), and corticosteroids; n = 170
Study: 19120077
Drug: Daclizumab induction,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab induction, MMF, reduced-dose tacrolimus delayed until the fifth day posttransplant, and corticosteroids; n = 172
Study: 16881381
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (HT)
Study: 16881381
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel
Study: 16881381
Drug: Matrix patch
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix patch
Study: 11342892
Drug: N-acetylcysteine, aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine, aspirin, and ranitidine
Study: 7947564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (age and sex matched individuals without oral cancer)
Study: 30724760
Drug: Medication-overuse headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-overuse headache (MOH) patients using simple analgesics
Study: 30724760
Drug: Medication-overuse headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-overuse headache (MOH) patients using centrally acting analgesics
Study: 30724760
Drug: Medication-overuse headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-overuse headache (MOH) patients classified as DSM-IV substance dependent
Study: 21966393
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg/d; n = 105)
Study: 21966393
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n = 111)
Study: 18838842
Drug: Pre-exercise hyperhydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise hyperhydration (26 ml of water x kg body mass(‐1) with 1.2 g glycerol x kg body mass(‐1))
Study: 11866251
Drug: Methadone dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone dose reduction with decrease instruction
Study: 11866251
Drug: Methadone dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone dose decrease
Study: 25556837
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance dose
Study: 8948744
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with morphine 4 mg and bupivacaine 0.125% 100 ml
Study: 8948744
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCA) with morphine 30 mg and ketorolac 90 mg in 100 ml of saline
Study: 15943220
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg once daily for 8 weeks
Study: 15943220
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg once daily for 8 weeks
Study: 16690590
Drug: Low folic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low folic acid diet (0 mg/kg)
Study: 16690590
Drug: Basal folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal folic acid diet (2 mg/kg)
Study: 16690590
Drug: High folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High folic acid diet (40 mg/kg)
Study: 15364642
Drug: Aesculus hippocastanum
Normalized name: Aesculus hippocastanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aesculus hippocastanum tablets (Aesculaforce 50mg), taken twice daily for 8 weeks.
Study: 29797436
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days)
Study: 29797436
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days) and amoxicillin (AMX; 500 mg/TID for 14 days)
Study: 27535654
Drug: Manual pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual pressure applied at the vaccination site for 10 seconds before injection
Study: 27535654
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection technique without manual pressure
Study: 24823599
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg, q.d.
Study: 23839593
Drug: Program combining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program combining pre-authorization requirement and systematic post-prescription review of carbapenems
Study: 14501599
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (10 mg/day testosterone cream)
Study: 11103826
Drug: Psychological therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy, relaxation training, and stress management
Study: 6146821
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg every evening
Study: 30463520
Drug: Patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient treatment modality
Study: 23185750
Drug: QM +
Normalized name: quinine sulfate Oral Tablet [QM-260]
Approvals — FDA: no, EMA: no, PMDA: no
Description: QM + chemotherapy
Study: 23185750
Drug: Pure chemotherapy
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure chemotherapy (control group)
Study: 19858256
Drug: Levofloxacin 7
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 7 mg/kg body weight
Study: 19858256
Drug: Levofloxacin 8
Normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 8 mg/kg twice a day
Study: 19858256
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg and 750 mg in healthy adults
Study: 16227840
Drug: Moxifloxacin hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop every 15 minutes for 4 doses before surgery (group 1)
Study: 16227840
Drug: Moxifloxacin hydrochloride
Normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop 4 times per day on the day before surgery plus the same preoperative regimen as group 1 (group 2)
Study: 12382950
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (1500 pulses ESWT at 0.12 mJ/mm2)
Study: 9272102
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement at 0.024 mg/kg per day
Study: 9272102
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement at 0.012 mg/kg per day